The Rho kinase inhibitor fasudil inhibits the migratory behaviour of 95-D lung carcinoma cells

Biomedicine and Pharmacotherapy

Volumn 64, Issue 1, 2010, Pages 58-62

  Yang, Xueying ^a,b   Liu, Ying ^c   Zong, Zhihong ^a   Tian, Dali ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Northern Hospital   (China)

^c Siping Central Hospital   (China)

Author keywords

Cancer; Migratory; Rho kinase

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ABC TRANSPORTER; ABC TRANSPORTER A3; ABC TRANSPORTER C1; ABC TRANSPORTER C3; ABC TRANSPORTER C5; ABC TRANSPORTER E1; BIOLOGICAL MARKER; FASUDIL; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MESSENGER RNA; MYOSIN PHOSPHATASE TARGETING SUBUNIT 1; RHO FACTOR; RHO KINASE; RHO KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; LUNG CARCINOMA; METASTASIS; METASTASIS INHIBITION; MIGRATION INHIBITION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ATP-BINDING CASSETTE TRANSPORTERS; CELL LINE, TUMOR; CELL MOVEMENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; HUMANS; INHIBITORY CONCENTRATION 50; LUNG NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; RHO-ASSOCIATED KINASES;

EID: 73349089312     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2009.08.006     Document Type: Article

References (28)

1. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 83 (2003) 1325-1358
2. Zicha D., Dobbie I.M., Holt M.R., et al. Rapid actin transport during cell protrusion. Science 300 (2003) 142-145
3. Amano M., Fukata Y., and Kaibuchi K. Regulation and functions of Rho-associated kinase. Exp Cell Res 261 (2000) 44-51
4. Redowicz M.J. Rho-associated kinase: involvement in the cytoskeleton regulation. Arch Biochem Biophys 364 (1999) 122-124
5. Izawa I., Amano M., Chihara K., et al. Possible involvement of the inactivation of the Rho-Rho-kinase pathway in oncogenic Ras-induced transformation. Oncogene 17 (1998) 2863-2871
6. Ridley A.J. Rho proteins and cancer. Breast Cancer Res Treat 84 (2004) 13-19
7. Sahai E., and Marshall C.J. RHO-GTPases and cancer. Nat Rev Cancer 2 (2002) 133-2142
8. Fritz G., Just I., and Kaina B. Rho-GTPases are over-expressed in human tumors. Int J Cancer 81 (1999) 682-687
9. Burbelo P., Wellstein A., and Pestell R.G. Altered Rho GTPase signaling pathways in breast cancer cells. Breast Cancer Res Treat 84 (2004) 43-48
10. van der Deen M., de Vries E.G., Timens W., et al. ATP-binding cassette (ABC) transporters in normal and pathological lung. Respir Res 6 (2005) 59
11. Shichijo S., Ishihara Y., Azuma K., Komatsu N., Higashimoto N., Ito M., et al. ABCE1, a member of ATP-binding cassette transporter gene, encodes peptides capable of inducing HLA-A2-restricted and tumor-reactive cytotoxic T lymphocytes in colon cancer patients. Oncol Rep (2005) 907-913
12. Ying H., Biroc S.L., Li W.W., Alicke B., et al. The Rho kinase inhibitor fasudil inhibits tumor progression in human and rat tumor models. Mol Cancer Ther 5 (2006) 2158-2164
13. Liu Y., Huo X., Pang X.F., et al. Musclin inhibits insulin activation of Akt/protein kinase B in rat skeletal muscle. J Int Med Res 36 (2008) 496-504
14. Levin E.G. Cancer therapy through control of cell migration. Curr Cancer Drug Targets 5 (2005) 505-518
15. Nakajima M., Hayashi K., Katayama K., et al. Wf-536 prevents tumor metastasis by inhibiting both tumor motility and angiogenic actions. Eur J Pharmacol 459 (2003) 113-120
16. Kader A.K., Liu J., Shao L., et al. Matrix metalloproteinase polymorphisms are associated with bladder cancer invasiveness. Clin Cancer Res 13 (2007) 2614-2620
17. Peng Z.M., Tang F.Q., and Wu E.S. Study of gene expression difference in lung carcinogenesis by cDNA microarray. Ai Zheng 23 (2004) 150-154
18. Chung A.W., Rauniyar P., Luo H., Hsiang Y.N., et al. Pressure distention compared with pharmacologic relaxation in vein grafting upregulates matrix metalloproteinase-2 and -9. J Vasc Surg 42 (2005) 747-756
19. Gómez-Hernández A., Sánchez-Galán E., Martín-Ventura J.L., et al. Atorvastatin reduces the expression of prostaglandin E2 receptors in human carotid atherosclerotic plaques and monocytic cells: potential implications for plaque stabilization. J Cardiovasc Pharmacol 47 (2006) 60-69
20. Sun G.P., Kohno M., Guo P., Nagai Y., et al. Involvements of Rho kinase and TGF-beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 17 (2006) 2193-2201
21. Takamura M., Sakamoto M., Genda T., et al. Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology 33 (2001) 577-581
22. Wilkinson S., Paterson H.F., and Marshall C.J. Cdc42-MRCK and Rho-ROCK signalling cooperate in myosin phosphorylation and cell invasion. Nat Cell Biol 7 (2005) 255-261
23. Kamai T., Tsujii T., Arai K., et al. Significant association of Rho/ROCK pathway with invasion and metastasis of bladder cancer. Clin Cancer Res 9 (2003) 2632-2641
24. Sharpe C.C., and Hendry B.M. Signaling: Focus on Rho in renal disease. J Am Soc Nephrol 14 (2003) 261-264
25. Umeda D., Yano S., Yamada K., et al. Involvement of 67-kDa laminin receptor-mediated myosin phosphatase activation in antiproliferative effect of epigallocatechin-3-O-gallate at a physiological concentration on Caco-2 colon cancer cells. Biochem Biophys Res Commun 371 (2008) 172-176
26. Davies S.P., Reddy H., Caivano M., et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351 (2000) 95-105
27. Shimokawa H., Seto M., Katsumata N., et al. Rho kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovasc Res 43 (1999) 1029-1039
28. Gottesman M., Fojo T., and Bates S. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2 (2002) 48-58